Emcure Pharmaceuticals’ initial public offering (IPO) has been booked 66.84 times on the third day of bidding as of 3:52 pm. The issue concludes today.
The categories earmarked for NII and QIB investors received the most subscriptions, at 47.98 and 193.06 times, respectively. Meanwhile, the retail sector fell behind, accounting for 6.83 times the subscription rate.
Before the issue opened, the business received ₹582 crore from anchor investors. Marquee investors in the anchor round included HDFC MF, ICICI Pru MF, SBI MF, Abu Dhabi Investment Authority, Goldman Sachs Asset Management, Nomura, and HDFC Life, among others.
The IPO consists of a new issuance of equity shares worth ₹800 crore and an offer for sale of 1.14 crore equity shares by promoters and current shareholders. Namita Thapar, of Shark Tank fame, will make roughly ₹127 crore from the stake sale under the OFS.
Emcure Pharmaceuticals is involved in the development, production, and global marketing of a wide range of pharmaceutical products in several important therapeutic areas.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.